Resmetirom, which was approved by the Food and Drug Administration (FDA) in March 2024, acts hepatocentrically to accelerate -oxidation, lower atherogenic lipoproteins, and deliver early signals necessary for fibrosis regression, all while largely avoiding systemic thyrotoxic effects
The 2.4mg strength, however, is specifically studied and approved for weight loss, with clinical trials showing significantly greater results in body weight reduction compared to the lower-dose versions
Anna Yoder, DNP, FNP-C, is a board-certified family nurse practitioner and founder of Telehealth NP
BPC-157 is usually tied more closely to localized repair, while TB-500 is more often discussed for broader tissue remodeling and cell migration
It is important to note that these recommendations are largely based on clinical experience and observational practice